TerminatedPhase 2NCT01784978
Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Associació per a la Recerca Oncologica, Spain
- Principal Investigator
- Joaquim Bellmunt, MD/PhDAssociacio Per la Recerca Oncológica (APRO)
- Intervention
- Sunitinib(drug)
- Enrollment
- 41 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2017
Study locations (10)
- Hopital Bordeaux University, Bordeaux, France
- ALEXANDRA General Hospital of Athens, Athens, Greece
- Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
- Hospital Universitario Central de Asturias, Oviedo, Principality of Asturias, Spain
- Hospital del Mar, Barcelona, Spain
- Hospital Universitario 12 de Octubre, Madrid, Spain
- Hospital Clínico San Carlos, Madrid, Spain
- Clara Campal. Hospital Sanchinarro, Madrid, Spain
- Hospital Universitario Virgen de la Victoria, Málaga, Spain
- Hospital General Universitario de Valencia, Valencia, Spain
Collaborators
Novartis · Pivotal S.L.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01784978 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07402109CBCT Guided Markerless SBRT for Renal Cell CancerErasmus Medical Center
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
See all trials for Acquired cystic disease-associated renal cell carcinoma →